Evaluation of the clinical efficiency of tocilizumab therapy, by using DAS 28, SDAI, CDAI indices and new 2011 EULAR/ACR remission criteria in patients with rheumatoid arthritis

Evaluation of the clinical efficiency of tocilizumab therapy, by using DAS 28, SDAI, CDAI indices and new 2011 EULAR/ACR remission criteria in patients with rheumatoid arthritis

Objective: to evaluate the clinical efficiency of tocilizumab (TCZ) from the DAS 28, SDAI, and CDAI indices and to estimate remission rates from the European League Against Rheumatism (EULAR) criteria, and the new remission criteria proposed by the EULAR and the American College of Rheumatology (ACR...

Full description

Saved in:
Bibliographic Details
Main Authors: Anastasia Sergeyevna Avdeyeva, E Yu Panasyuk, E N Aleksandrova, E L Nasonov
Format: Article
Language:Russian
Published: IMA PRESS LLC 2012-04-01
Series:Научно-практическая ревматология
Subjects:
das 28
sdai
cdai
rheumatoid arthritis
tocilizumab
remission
Online Access:https://rsp.mediar-press.net/rsp/article/view/1162
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items